

Anti-HGFR/c-Met Antibody (Telisotuzumab)

Introduction

Telisotuzumab (ABT-700) is a humanized recombinant bivalent antibody, a therapeutic antibody targeting hepatocyte growth factor receptor (MET), which can bind to c-Met with high affinity and inhibit c-Met signaling. Telisotuzumab has anti-tumor activity.

Product parameters

Alternative Names	h224G11, ABT-700
Target Accession	P08581
Target	HGFR / c-Met
CAS number	1781223-80-0
Molecular Weight	146.1 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	The purity of Anti-HGFR/c-Met Antibody (Telisotuzumab) is 99.49%, determined by SEC-HPLC.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80 °C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

